Fresenius Medical Care AG & Co. KGaA (FMS) Projected to Post Quarterly Earnings on Tuesday

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is anticipated to issue its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of $0.67 per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 6:00 AM ET.

Fresenius Medical Care AG & Co. KGaA Stock Down 0.1%

FMS opened at $24.44 on Tuesday. Fresenius Medical Care AG & Co. KGaA has a one year low of $20.94 and a one year high of $30.46. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.36. The stock has a market capitalization of $14.17 billion, a P/E ratio of 17.84, a price-to-earnings-growth ratio of 0.77 and a beta of 0.90. The business’s 50-day simple moving average is $23.24 and its 200-day simple moving average is $24.48.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

Several institutional investors have recently bought and sold shares of the company. CIBC Private Wealth Group LLC raised its position in Fresenius Medical Care AG & Co. KGaA by 398.2% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock worth $36,000 after buying an additional 1,103 shares during the last quarter. Arax Advisory Partners increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 121.6% during the fourth quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock worth $38,000 after acquiring an additional 885 shares during the period. Kestra Advisory Services LLC purchased a new position in Fresenius Medical Care AG & Co. KGaA during the fourth quarter worth about $48,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Fresenius Medical Care AG & Co. KGaA during the fourth quarter worth about $58,000. Finally, Group One Trading LLC acquired a new stake in Fresenius Medical Care AG & Co. KGaA in the third quarter valued at about $74,000. 8.37% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on FMS. Zacks Research cut Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Wall Street Zen raised shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. Erste Group Bank downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. Truist Financial set a $28.00 price objective on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Monday, January 5th. Finally, Weiss Ratings lowered shares of Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 5th. Five research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Fresenius Medical Care AG & Co. KGaA currently has an average rating of “Reduce” and a consensus target price of $28.00.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.